Navigation Links
ACTUS Appoints New Members to Its Management Team
Date:10/1/2013

Oro Valley, AZ (PRWEB) October 01, 2013

ACTUS Biotechnologies has recently added four highly experienced industry professionals to its management team, further broadening the capabilities of its existing team, and adding more than a century of experience to the organization. The ACTUS Biotechnologies management team serves in a duplicate role in each of the accelerator’s subsidiaries, Convoy Therapeutics and EnduRx Pharmaceuticals. These personnel round out a team that already includes executive and senior management in Regulatory Affairs, Quality Assurance, and Business Development.

Dr. Deborah Slee has joined ACTUS as the Vice President of Research & Development, overseeing a team of fifteen personnel from various disciplines serving in full-time and consulting capacities within the organization. She is also leading efforts at the ACTUS laboratory being established at the Janseen incubator in La Jolla, CA. Dr. Slee’s career includes more than twenty years of industry experience in a variety of therapeutic areas leading development efforts. She is a co-founder of both Aspyrian Therapeutics and CendR Therapeutics and previously led efforts at both Ontogen and Neurocrine Biosciences. Dr. Slee received her Ph.D. from the University of Exeter and performed post-doctoral research at The Scripps Research Institute in La Jolla, CA.

Also joining the ACTUS Research & Development team is Dr. Sarah Hudson, as the Director of Project Management. With more than ten years of experience in research and development and project management in biopharmaceutical companies, including Neurocrine Biosciences, Exelixis, and most recently CovX, a division of Pfizer, she brings an outstanding track record to the ACTUS team. Dr. Hudson earned her Ph.D. at the University of Bristol and performed her post-doctoral work at Neurocrine Biosciences.

Mr. Brandon French, an accomplished healthcare operations and business development professional, has joined ACTUS as its Vice President of Operations. His experience includes more than twenty years in healthcare real estate and financial management. Mr. French earned his B.S. in Finance from the Minder School of Business at Oklahoma City University.

ACTUS Biotechnologies has added Ms. Tanya Paschke as their new Director of Operations. Ms. Paschke’s career includes more than 25 years of experience in the biopharmaceutical industry with roles of increasing responsibility in operational management of facilities, core research and development efforts and sales and marketing in major pharmaceutical and academic institutions.

About ACTUS Biotechnologies

ACTUS Biotechnologies is an accelerator company, commercializing the most impactful biopharmaceutical technologies; bridging the gap between academic research and industrial commercialization. The ACTUS Biotechnologies management team includes an exceptional team of individuals with decades of expertise in all aspects of the Life Sciences business sector. The team’s singular mission is the rapid growth and commercialization of technologies that have the potential to positively impact both the practice of medicine and patient quality of life; driven by innovation, forward thinking, integrity and empowerment.

During its licensing process, the ACTUS team performs extensive review and due diligence, ensuring the technology meets ACTUS’ standard of excellence. Licensed technologies are spun off into new, wholly-owned subsidiaries and provided with initial capital, and all operational support required to accelerate commercialization including: Operations, Research & Development, Project Planning, Business Development, and Legal. Current subsidiaries within the accelerator include Convoy Therapeutics (http://www.convoytx.com) and EnduRx Pharmaceuticals (http://www.endurxpharma.com).

Read the full story at http://www.prweb.com/releases/2013/10/prweb11180794.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related biology technology :

1. Immune Design Appoints Stephen R. Brady Chief Business Officer
2. DiaVacs, Inc. Appoints Orville Kolterman, M.D. As Chief Medical Officer
3. Sanomedics International Holdings, Inc. appoints new Chairman of the Board and installs new Director of Business Development.
4. Solulink Appoints Life Science Industry Veteran Jack Ball as Chief Executive Officer
5. Cold Spring Harbor Laboratory Appoints Teri F. Willey to Accelerate Commercialization Efforts
6. Senn Chemicals Appoints New Chief Executive Officer
7. Novelda Appoints Alf-Egil Bogen as Chief Executive Officer to Lead the Company to the Next Level
8. Creabilis Appoints Professor Gil Yosipovitch and Professor Praveen Anand to its Scientific Advisory Board
9. Alexander Proudfoot Appoints Executive Vice President for Life Sciences
10. KemPharm, Inc. Appoints Gordon K. "Rusty" Johnson as Chief Operating Officer and Chief Financial Officer
11. KaloBios Appoints Donald R. Joseph as Chief Legal Officer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... ... June 23, 2016 , ... ClinCapture, the ... Convention Center and will showcase its product’s latest features from June 26 to ... a scientific poster on Disrupting Clinical Trials in The Cloud during the conference. ...
(Date:6/23/2016)... ... June 23, 2016 , ... Velocity ... intelligent tools designed, tuned and optimized exclusively for Okuma CNC machining centers at ... result of a collaboration among several companies with expertise in toolholding, cutting tools, ...
(Date:6/23/2016)... India , June 23, 2016 ... media market research report to its pharmaceuticals section ... profiles, product details and much more. ... spread across 151 pages, profiling 15 companies and ... available at http://www.reportsnreports.com/reports/601420-global-cell-culture-media-industry-2016-market-research-report.html . ...
(Date:6/22/2016)... , June 22, 2016 Research and ... Global Markets" report to their offering. ... billion in 2014 from $29.3 billion in 2013. The market is ... of 13.8% from 2015 to 2020, increasing from $50.6 billion in ... projected product forecasts during the forecast period (2015 to 2020) are ...
Breaking Biology Technology:
(Date:4/13/2016)... , April 13, 2016  IMPOWER physicians supporting ... are setting a new clinical standard in telehealth thanks ... By leveraging the higi platform, IMPOWER patients can routinely ... pulse and body mass index, and, when they opt ... and convenient visit to a local retail location at ...
(Date:3/31/2016)... , March 31, 2016  Genomics firm Nabsys has ... CEO, Barrett Bready , M.D., who returned to ... the original technical leadership team, including Chief Technology Officer, ... Product Development, Steve Nurnberg and Vice President of Software ... the company. Dr. Bready served as CEO ...
(Date:3/23/2016)... WAKEFIELD, Massachusetts , March 23, 2016 ... kombiniert im Interesse erhöhter Sicherheit Gesichts- und ... Xura, Inc. (NASDAQ: MESG ... heute bekannt, dass das Unternehmen mit SpeechPro ... insbesondere aus der Finanzdienstleistungsbranche, wird die Möglichkeit ...
Breaking Biology News(10 mins):